In recent years, Roche Holding's stock performance has been mixed. There is some investor concern over a modest outlook for 2024 and shares have fallen about 18% over the last three years. Yet there are those who argue that the stock, at $33, is undervalued. Roche has made strategic moves such as a $3.1 billion deal for an obesity drug maker, and purchasing U.S. rights to Roivant's bowel disease drug for $7.1 billion. It also purchased part of LumiraDx diagnostics platform for $295 million and entered the weight loss drug market with the acquisition of Carmot Therapeutics.
However, there have been financial challenges for Roche. Its Q1 sales were down and it faced currency headwinds and lower COVID-19 sales. Despite this, the company still increased its dividend to CHF 9.60. Additionally, Roche's Swiss stock outperformed, likely due to its recent business moves, and the company is expecting a return to growth in 2024 after a drop in COVID sales. Despite some setbacks, Roche continues to be recognized as leader in bio-tech, recently winning an FDA Priority Review Tag for its Xolair product.
Roche Stocks News Analytics from Wed, 23 Aug 2023 07:00:00 GMT to Thu, 02 May 2024 11:21:25 GMT - Rating 5 - Innovation 3 - Information 8 - Rumor -4
